A Phase 1 interventional study of capecitabine [Xeloda] in Glioma, sponsored by Hoffmann-La Roche. Completed at 9 sites in United States. Open to participants aged 3 Years to 21 Years. Per ClinicalTrials.gov, last updated 2016-12-07.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.
Among the 851 studies in Glioma with a site in United States, this one is the 407th largest by enrollment of the 737 interventional ones that give a count, is one of 25 that started in 2007, is one of 338 in phase 1, and was the 166th registered.
1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.
Browse Glioma studies →142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:
Nuvation Bio Inc. · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 1–21
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
Neonc Technologies, Inc. · Sites in United States
Ages 5–18
Children's National Research Institute · Sites in United States
Ages 3–25
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.
This study: 3 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
851 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 430 · Phase 2 320 · Phase 3 21 · Phase 4 6
First in 1979; this study’s year is marked. 25 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 32 across 1,075 interventional studies indexed under Glioma.
Median enrollment 30 across the 737 interventional studies, 69 across the 77 observational. Of the 564 that completed or were terminated, 203 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 851 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 5 studies filed under Glioma — fewer than ten, so there is no comparison to draw.
88 of the studies in Glioma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
| NCT03510208Stanford UniversityPanitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | 2026-11 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
Add all 88 to your calendar (.ics) → With an account.
Among the 851 studies in Glioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the maximum tolerated dose, and dose-limiting toxicities, of Xeloda administered concurrently with radiation therapy, in children with newly diagnosed diffuse intrinsic brain stem gliomas and high grade gliomas. Xeloda will be administered twice daily, at a starting dose of 500mg/m2 bid, beginning within 24 hours of the start of radiation therapy. Subsequent dose escalations will be in increments of 30%, using a standard dose escalation schema. Post-radiation therapy with Xeloda will continue after a 2 week break. The anticipated time on study treatment is 3-12 months, and the target sample size will not exceed 30 evaluable patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: capecitabine [Xeloda]
500mg/m2 po bid (starting dose)
Maximum Tolerated Dose (MTD) of Capecitabine.
The MTD was the dose level at which six evaluable patients had been treated and at most one patient experienced a dose limiting toxicity (DLT) and the next highest dose level was too toxic. Dose escalation occurred if 0 out of 3 or at most 1 out of 6 patients experienced DLT while being treated at a dose level; otherwise the dose was declared unsafe and thus above the MTD.
Time frame: Upto 11 weeks.
Dose Limiting Toxicities (DLTs)
DLT was defined as any of the following events occurring during the 11 week dose-finding period: any event that leads to interruption of planned radiation for 5 consecutive days or 10 days total; Grade 4 neutropenia or thrombocytopenia; Grade 3 thrombocytopenia that required a platelet transfusion on 2 or more occasions; any Grade 3 or 4 non-hematologic toxicity (with the exception of grade 3 nausea or vomiting of less than 5 days duration, Grade 3 transaminases that returned to baseline value within 7 days of study drug interruption and that did not recur upon re-challenge with study drug, and/or Grade 3 fever or infection of \<5 days duration); Grade 2 non-hematologic toxicities that persisted for \>7 days and required treatment interruption, or any other capecitabine-related adverse events that required need for dose reduction or permanent cessation of therapy, interruption of study drug for \>7 days or recurred on re-challenge with capecitabine rapidly disintegrating tablets (RDTs).
Time frame: Upto 11 weeks
Number of Participants With Adverse Events (AE)
An AE is an unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Toxicity was monitored and graded according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Adverse events that were not included in the CTCAEv3.0 were reported and graded under the other AE within the appropriate category.
Time frame: Up to 06 years
Number of Participants With Baseline Shift From Normal to Low or High in Hematology Parameters
For hematology, the parameters assessed were: Hemoglobin, hematocrit, platelet count, RBC, WBC, lymphocytes, monocytes,granulocytes (blasts), neutrophils(segs, bands),eosinophils and basophils.
Time frame: Up to 06 years
Number of Participants With Baseline Shift From Normal to Low or High in Blood Chemistry Parameters
For blood chemistry, the parameters assessed were: Sodium, potassium, calcium, magnesium, chloride, bicarbonate, total protein, albumin, alkaline phosphatase, alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), Lactate dehydrogenase (LDH), total bilirubin, direct bilirubin, indirect bilirubin, creatinine (serum creatinine or creatinine clearance), glucose.
Time frame: Up to 06 years
Maximum Observed Plasma Concentration (Cmax) of Capecitabine and Its Metabolites (5'-Deoxy-5-Fluorocytidine [5'-DFCR], 5'-Deoxy-5-Fluorouridine [5'-DFUR], 5-Fluorouracil [5-FU] and Alpha-fluoro-beta-alanine [FBAL])
The maximum observed plasma concentration of capecitabine and its metabolites. Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).
Time frame: Day 1 and Day 14
Time to Maximum Plasma Concentration (Tmax) of Capecitabine and Its Metabolites (5'-DFCR, 5'-DFUR, 5-FU and FBAL)
Tmax is the corresponding time at which Cmax occurs of capecitabine and its metabolites.Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).
Time frame: Day 1 and Day 14
The Area Under the Plasma Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Capecitabine and Its Metabolites (5'-DFCR, 5'-DFUR, 5-FU and FBAL)
AUC last concentration of capecitabine and its metabolites. Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).
Time frame: Day 1 and Day 14
Anti Tumor Activity
Tumor response refers to the best response prior to failure (disease progression, death or second malignancy).
Time frame: Up to 6 years
All participants in the study were enrolled at Pediatric Brain Tumor Consortium (PBTC) institutions in the United States of America (USA), from 24 May 2007 through 27 October 2009.
| Milestone | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| Started | 4 | 14 | 6 |
| Completed | 0 | 9 | 2 |
| Not completed | 4 | 5 | 4 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Death | 3 | 3 | 4 |
| Withdrew: Violation of selection criteria at entry | 0 | 1 | 0 |
| Withdrew: Failure to return | 0 | 1 | 0 |
The MTD was the dose level at which six evaluable patients had been treated and at most one patient experienced a dose limiting toxicity (DLT) and the next highest dose level was too toxic. Dose escalation occurred if 0 out of 3 or at most 1 out of 6 patients experienced DLT while being treated at a dose level; otherwise the dose was declared unsafe and thus above the MTD.
| milligrams | Capecitabine (Overall) |
|---|---|
| Maximum Tolerated Dose (MTD) of Capecitabine. | 650 |
DLT was defined as any of the following events occurring during the 11 week dose-finding period: any event that leads to interruption of planned radiation for 5 consecutive days or 10 days total; Grade 4 neutropenia or thrombocytopenia; Grade 3 thrombocytopenia that required a platelet transfusion on 2 or more occasions; any Grade 3 or 4 non-hematologic toxicity (with the exception of grade 3 nausea or vomiting of less than 5 days duration, Grade 3 transaminases that returned to baseline value within 7 days of study drug interruption and that did not recur upon re-challenge with study drug, and/or Grade 3 fever or infection of \<5 days duration); Grade 2 non-hematologic toxicities that persisted for \>7 days and required treatment interruption, or any other capecitabine-related adverse events that required need for dose reduction or permanent cessation of therapy, interruption of study drug for \>7 days or recurred on re-challenge with capecitabine rapidly disintegrating tablets (RDTs).
| Participants | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| Dose Limiting Toxicities (DLTs) | 0 | 3 | 3 |
An AE is an unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Toxicity was monitored and graded according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Adverse events that were not included in the CTCAEv3.0 were reported and graded under the other AE within the appropriate category.
| Participants | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| Number of Participants With Adverse Events (AE) | 3 | 12 | 6 |
For hematology, the parameters assessed were: Hemoglobin, hematocrit, platelet count, RBC, WBC, lymphocytes, monocytes,granulocytes (blasts), neutrophils(segs, bands),eosinophils and basophils.
| Participants | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| Haematocrit, normal to low, n=3,1,5 | 2 | 1 | 4 |
| Haematocrit, normal to high, n=3,1,5 | 0 | 0 | 0 |
| Hemoglobin, normal to low, n=4,2,6 | 0 | 0 | 2 |
| Hemoglobin, normal to high, n=4,2,6 | 0 | 0 | 0 |
| White blood cell, normal to low, n=3,1,5 | 0 | 0 | 0 |
| White blood cell, normal to high, n=3,1,5 | 1 | 1 | 1 |
| Platelets, normal to low, n=4,2,6 | 0 | 1 | 0 |
| Platelets, normal to high, n=4,2,6 | 0 | 0 | 1 |
| Red blood cells, normal to low, n=3,1,3 | 2 | 0 | 1 |
| Red blood cells, normal to high, n=3,1,3 | 0 | 1 | 0 |
| Neutrophils (segmented), normal to low , n=3,0,5 | 0 | 0 | 0 |
| Neutrophils (segmented), normal to high, n=3,0,5 | 0 | 0 | 0 |
| Basophils (relative), normal to low, n=0,1,2 | 0 | 0 | 0 |
| Basophils (relative), normal to high, n=0,1,2 | 0 | 1 | 2 |
| Lymphocytes (relative), normal to low, n=3,1,5 | 0 | 0 | 0 |
| Lymphocytes (relative), normal to high, n=3,1,5 | 0 | 0 | 0 |
| Monocytes (relative), normal to low, n=3,1,4 | 0 | 0 | 0 |
| Monocytes (relative), normal to high, n=3,1,4 | 1 | 0 | 3 |
| Eosinophils (relative), normal to low, n=1,1,3 | 0 | 1 | 0 |
| Eosinophils (relative), normal to high, n=1,1,3 | 0 | 0 | 0 |
For blood chemistry, the parameters assessed were: Sodium, potassium, calcium, magnesium, chloride, bicarbonate, total protein, albumin, alkaline phosphatase, alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), Lactate dehydrogenase (LDH), total bilirubin, direct bilirubin, indirect bilirubin, creatinine (serum creatinine or creatinine clearance), glucose.
| Participants | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| Lactic dehydrogenase, normal to low, n=0,0,0 | 0 | 0 | 0 |
| Lactic dehydrogenase, normal to high, n=0,0,0 | 0 | 0 | 0 |
| Indirect bilirubin, normal to low, n=1,1,1 | 0 | 0 | 0 |
| Indirect bilirubin, normal to high, n=1,1,1 | 0 | 1 | 0 |
| BUN, normal to low, n=3,1,5 | 0 | 0 | 2 |
| BUN, normal to high, n=3,1,5 | 0 | 1 | 1 |
| Alkaline phosphatase, normal to low, n=1,1,4 | 0 | 0 | 1 |
| Alkaline phosphatase, normal to high, n=1,1,4 | 0 | 0 | 0 |
| Direct blirubin, normal to low, n=2,1,1 | 0 | 0 | 0 |
| Direct bilirubin, normal to high, n=2,1,1 | 0 | 0 | 0 |
| Total bilirubin, normal to low, n=4,2,6 | 0 | 0 | 0 |
| Total bilirubin, normal to high, n=4,2,6 | 0 | 0 | 0 |
| Fasting glucose, normal to low, n=1,0,4 | 0 | 0 | 0 |
| Fasting glucose, normal to high, n=1,0,4 | 0 | 0 | 0 |
| Protein, normal to low, n=1,0,2 | 1 | 0 | 1 |
| Protein, normal to high, n=1,0,2 | 0 | 0 | 0 |
| Serum albumin, normal to low, n=3,1,5 | 2 | 0 | 1 |
| Serum albumin, normal to high, n=3,1,5 | 0 | 0 | 0 |
| Serum creatinine, normal to low, n=4,2,6 | 0 | 0 | 0 |
| Serum creatinine, normal to high, n=4,2,6 | 0 | 0 | 2 |
| ASAT (SGOT), normal to low, n=1,0,4 | 0 | 0 | 0 |
| ASAT (SGOT), normal to high, n=1,0,4 | 0 | 0 | 2 |
| ALAT (SGPT), normal to low, n=4,2,6 | 0 | 0 | 0 |
| ALAT (SGPT), normal to high, n=4,2,6 | 2 | 2 | 4 |
| Calcium, normal to low, n=3, 1,5 | 1 | 1 | 0 |
| Calcium, normal to high, n=3,1,5 | 0 | 0 | 1 |
| Phosphate, normal to low, n=3,1,5 | 1 | 0 | 1 |
| Phosphate, normal to high, n=3,1,5 | 0 | 0 | 1 |
| Potassium, normal to low, n=3, 1,5 | 2 | 0 | 0 |
| Potassium, normal to high, n=3,1,5 | 0 | 1 | 0 |
| Sodium, normal to low, n=3,1,5 | 1 | 1 | 3 |
| Sodium, normal to high, n=3,1,5 | 0 | 0 | 0 |
| Magnesium, normal to low, n=3,1,5 | 0 | 0 | 0 |
| Magnesium, normal to high, n=3,1,5 | 1 | 1 | 0 |
| Chloride, normal to low, n=3,1,5 | 0 | 0 | 1 |
| Chloride, normal to high, n=3,1,5 | 0 | 1 | 1 |
| Bicarbonate, normal to low, n=3,0,5 | 0 | 0 | 0 |
| Bicarbonate, normal to high, n=3,0,5 | 0 | 0 | 3 |
The maximum observed plasma concentration of capecitabine and its metabolites. Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).
| ng/mL | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| Capecitabine, Day 1, n= 2, 4, 3 | 1440 ± 750 | 3080 ± 1340 | 1890 ± 1420 |
| Capecitabine, Day 14, n=2,2,2 | 2100 ± 1770 | 5440 ± 3270 | 3710 ± 156 |
| 5'-DFCR, Day 1, n=2,4,3 | 2050 ± 813 | 2190 ± 626 | 2180 ± 1690 |
| 5'-DFCR, Day 14, n=2,2,2 | 2980 ± 2020 | 3500 ± 1470 | 3200 ± 233 |
| 5'-DFUR, Day 1, n=2,4,3 | 1910 ± 834 | 2640 ± 1700 | 3770 ± 3300 |
| 5'-DFUR, Day 14, n=2,2,2 | 3300 ± 2800 | 3120 ± 445 | 5020 ± 1220 |
| FBAL, Day 1, n=2,4,3 | 1350 ± 134 | 1740 ± 365 | 2050 ± 1640 |
| FBAL, Day 14, n=2,2,2 | 1770 ± 410 | 2430 ± 84.9 | 2140 ± 304 |
Tmax is the corresponding time at which Cmax occurs of capecitabine and its metabolites.Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).
| Hour | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| Capecitabine, Day 1, n= 2, 4, 3 | 0.58 (0.17 to 1) | 0.63 (0.25 to 1) | 0.85 (0.83 to 10) |
| Capecitabine, Day 14, n=2,2,2 | 1.33 (0.17 to 2.48) | 0.82 (0.8 to 0.83) | 0.61 (0.5 to 0.72) |
| 5'-DFCR, Day 1, n=2,4,3 | 1.0 (1.0 to 1.0) | 0.75 (0.50 to 2.50) | 1.55 (0.85 to 10) |
| 5'-DFCR, Day 14, n=2,2,2 | 1.49 (0.5 to 2.48) | 1.18 (0.5 to 1.53) | 0.61 (0.5 to 1.53) |
| 5'-DFUR, Day 1, n=2,4,3 | 1 (1 to 1) | 0.9 (0.7 to 2.5) | 1.5 (0.75 to 10) |
| 5'-DFUR, Day 14, n=2,2,2 | 1.5 (0.5 to 2.5) | 0.82 (0.8 to 0.83) | 0.61 (0.5 to 0.72) |
| 5-FU, Day 1, n=2,4,3 | 1 (1 to 1) | 0.75 (0.5 to 2.5) | 1.5 (0.75 to 10) |
| 5-FU, Day 14, n=2,2,2 | 1.5 (0.5 to 2.5) | 0.83 (0.8 to 0.83) | 1 (0.5 to 1.5) |
| FBAL, Day 1, n=2,4,3 | 2.53 (2.5 to 2.53) | 1.5 (1.5 to 2.5) | 1.55 (1.42 to 10) |
| FBAL, Day 14, n=2,2,2 | 1.74 (1 to 2.5) | 2.2 (1.5 to 2.8) | 2.03 (1.57 to 2.5) |
AUC last concentration of capecitabine and its metabolites. Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).
| h*ng/mL | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| Capecitabine, Day 1, n= 2, 4, 3 | 3370 ± 607 | 5160 ± 3700 | 3470 ± 1170 |
| Capecitabine, Day 14, n=2,2,2 | 2890 ± 655 | 9660 ± 3340 | 5670 ± 971 |
| 5'-DFCR, Day 1, n=2,4,3 | 5250 ± 755 | 5140 ± 3440 | 4180 ± 2380 |
| 5'-DFCR, Day 14, n=2,2,2 | 4300 ± 27.2 | 9250 ± 1400 | 6520 ± 452 |
| 5'-DFUR, Day 1, n=2,4,3 | 4790 ± 784 | 4300 ± 1600 | 6650 ± 3740 |
| 5'-DFUR, Day 14, n=2,2,2 | 4240 ± 929 | 8010 ± 1890 | 10500 ± 445 |
| 5-FU Day 1, n=2,4,3 | 81.6 ± 29.7 | 114 ± 40.9 | 271 ± 205 |
| 5-FU Day 14, n=2,2,2 | 181 ± 84.7 | 253 ± 16.3 | 499 ± 78.8 |
| FBAL, Day 1, n=2,4,3 | 5990 ± 951 | 8110 ± 1640 | 7010 ± 4490 |
| FBAL, Day 14, n=2,2,2 | 5720 ± 690 | 10700 ± 574 | 10400 ± 1760 |
Tumor response refers to the best response prior to failure (disease progression, death or second malignancy).
No measurements were reported for this outcome.
Collected over Up to 6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine 500 mg/m^2 | — | 2/4 (50%) | 3/4 (75%) |
| Capecitabine 650 mg/m^2 | — | 1/12 (8.3%) | 12/12 (100%) |
| Capecitabine 850 mg/m^2 | — | 3/6 (50%) | 6/6 (100%) |
| Event | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| HydrocephalusNervous system disorders | 1/4 | 0/12 | 0/6 |
| LeukopeniaBlood and lymphatic system disorders | 1/4 | 0/12 | 0/6 |
| ConvulsionNervous system disorders | 0/4 | 0/12 | 1/6 |
| Skin ExfoliationSkin and subcutaneous tissue disorders | 0/4 | 0/12 | 1/6 |
| Abdominal InfectionInfections and infestations | 0/4 | 0/12 | 1/6 |
| Blood Creatinine IncreasedInvestigations | 0/4 | 0/12 | 1/6 |
| Dermatitis ExfoliativeSkin and subcutaneous tissue disorders | 0/4 | 1/12 | 0/6 |
| PainGeneral disorders | 0/4 | 1/12 | 0/6 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/4 | 1/12 | 0/6 |
| Event | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 |
|---|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 3/4 | 10/12 | 3/6 |
| LeukopeniaBlood and lymphatic system disorders | 3/4 | 10/12 | 2/6 |
| Alanine aminotransferase increasedInvestigations | 1/4 | 9/12 | 3/6 |
| VomitingGastrointestinal disorders | 2/4 | 9/12 | 2/6 |
| Abdominal painGastrointestinal disorders | 0/4 | 4/12 | 4/6 |
| NauseaGastrointestinal disorders | 1/4 | 2/12 | 4/6 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 1/4 | 8/12 | 4/6 |
| Neutrophil countInvestigations | 2/4 | 4/12 | 1/6 |
| Platelet count decreasedInvestigations | 2/4 | 5/12 | 0/6 |
| HypokalaemiaMetabolism and nutrition disorders | 2/4 | 3/12 | 2/6 |
Intent to treat population defined as all participants enrolled.
| Age, Continuous(years) | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 | Total |
|---|---|---|---|---|
| Mean | 7.5 ± 1.73 | 8.4 ± 2.65 | 13 ± 3.41 | 9.37 ± 3.39 |
| Gender(Participants) | Capecitabine 500 mg/m^2 | Capecitabine 650 mg/m^2 | Capecitabine 850 mg/m^2 | Total |
|---|---|---|---|---|
| Female | 1 | 12 | 2 | 15 |
| Male | 3 | 2 | 4 | 9 |
The record gives a start of May 2007, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capecitabine